As elevated LCN2 levels implicate ongoing gut inflammation and progressive spinal ankylosis, our findings suggest that normalization of LCN2 through modulation of PPARγ could be viewed as a treatment target in AS and IBD. This evidence concerns the gene LCN2 and inflammatory bowel disease.